BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed ABBV catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:75f8452e85f5848e823f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P2/P3 readout (est.): ATMOSPHERE
DESCRIPTION:Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Th
 erapy Administered Via Subretinal Delivery One Time in Participants With n
 AMD\nNCT04704921 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nDate precision: month (shown on the first day)\nTicker ABBV (confide
 nce 0.9)\nSource: https://clinicaltrials.gov/study/NCT04704921\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04704921
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1817f81049549aaae5ca@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P2 readout (est.): Study to Assess Adverse Events and Change i
 n Disease Activity in Previously Treated Adult Participants Receiving Intr
 avenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Co
 mbination With IV Fluorouracil\, Folinic Acid\, and Bevacizumab
DESCRIPTION:Study to Assess Adverse Events and Change in Disease Activity i
 n Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-40
 0 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fl
 uorouracil\, Folinic Acid\, and Bevacizumab\nNCT06107413 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nDate precision: month (shown on the
  first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinicaltrials.
 gov/study/NCT06107413\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06107413
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36ec4c88770f8ba5b331@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABBV P3 readout (est.): Intrepid
DESCRIPTION:A Study to Assess Disease Activity and Safety of Lutikizumab in
  Adult and Adolescent Participants With Moderate to Severe Hidradenitis Su
 ppurativa\nNCT06468228 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker ABBV (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT06468228\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06468228
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:70fc1810224f51ad694f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ABBV P2/P3 readout (est.): LIVIGNO-2
DESCRIPTION:A Study to Assess the Dose\, Adverse Events\, and Change in Dis
 ease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combinat
 ion With Budigalimab as an IV Solution in Adult Participants With Hepatoce
 llular Carcinoma (HCC)\nNCT06109272 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITIN
 G | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nT
 icker ABBV (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 6109272\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06109272
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ceffe596572998f04918@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ABBV P3 readout (est.): Start Up Japan
DESCRIPTION:Safety and Efficacy of Upadacitinib in Combination With Topical
  Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan 
 With Moderate to Severe Atopic Dermatitis\nNCT06701331 | PHASE3 | ACTIVE_N
 OT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nTicker ABBV (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT06701331\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06701331
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ac13bf6c4c9def48651@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P1/P2 readout (est.): IMGN632 as Monotherapy or With Venetocla
 x and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Le
 ukemia
DESCRIPTION:IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine fo
 r Participants With CD123-Positive Acute Myeloid Leukemia\nNCT04086264 | P
 HASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nDate precision
 : month (shown on the first day)\nTicker ABBV (confidence 0.9)\nSource: ht
 tps://clinicaltrials.gov/study/NCT04086264\nScheduling/reference data from
  public records\; dates can move. Not investment\, legal or medical advice
 .
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04086264
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:551825c4dd9982bcf29a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study of Ocular Toxicity Evaluation and M
 itigation During Treatment With Mirvetuximab Soravtansine in Participants 
 With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
DESCRIPTION:A Study of Ocular Toxicity Evaluation and Mitigation During Tre
 atment With Mirvetuximab Soravtansine in Participants With Recurrent Ovari
 an Cancer With High Folate Receptor-Alpha Expression\nNCT06365853 | PHASE2
  | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinic
 altrials.gov/study/NCT06365853\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06365853
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:74646cc7e9eb523707be@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study to Assess Molecular Changes in Adul
 t Participants With Moderate to Severe Hidradenitis Suppurativa or With Mo
 derate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lu
 tikizumab
DESCRIPTION:A Study to Assess Molecular Changes in Adult Participants With 
 Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Ato
 pic Dermatitis Receiving Subcutaneous Injections of Lutikizumab\nNCT065246
 35 | PHASE2 | RECRUITING | sponsor: AbbVie\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker ABBV (confidence 0.9)\nSource: https://clinic
 altrials.gov/study/NCT06524635\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06524635
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f26e5d68487d43e703f2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): AURORA
DESCRIPTION:A Study to Investigate the Safety and Efficacy of MEDI0618 Comp
 ared to Placebo in Adult Participants With Episodic Migraine\nNCT06602479 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AbbVie\nPrimary completion dat
 e (ESTIMATED)\; top-line results usually follow later.\nDate precision: mo
 nth (shown on the first day)\nTicker ABBV (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT06602479\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06602479
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c89fa51f5bd090122b1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ABBV P2 readout (est.): A Study to Evaluate Different Targeted Ther
 apies for Patients With Rheumatoid Arthritis
DESCRIPTION:A Study to Evaluate Different Targeted Therapies for Patients W
 ith Rheumatoid Arthritis\nNCT06972446 | PHASE2 | RECRUITING | sponsor: Abb
 Vie\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nDate precision: month (shown on the first day)\nTicker ABBV (conf
 idence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06972446\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06972446
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1ad6806cdfe7e8902280@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-10-23: SKYRIZI (BLA761105 SUPPL53)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:67a32cde24cd6d0a733f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:ABBV APPROVAL: JUVMO\; JUVMO (COPACKAGED)
DESCRIPTION:Approved 2026-09-25: JUVMO\; JUVMO (COPACKAGED) (NDA220415 ORIG
 1)\nConfidence: confirmed\nTicker ABBV (confidence 0.9)\nSource: https://w
 ww.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Ap
 plNo=220415\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220415
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:065bf5fb095e08945760@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-06-26: SKYRIZI (BLA761105 SUPPL45)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f8b906b24898eba9e353@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-06-12: SKYRIZI (BLA761105 SUPPL44)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ccb5086da2f9bff3389a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260527
DTEND;VALUE=DATE:20260528
SUMMARY:ABBV APPROVAL: DECNUPAZ
DESCRIPTION:Approved 2026-05-27: DECNUPAZ (BLA761460 ORIG1)\nConfidence: co
 nfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761460\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761460
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:808d65b9cd864f6d0915@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260521
DTEND;VALUE=DATE:20260522
SUMMARY:ABBV APPROVAL: LINZESS
DESCRIPTION:Approved 2026-05-21: LINZESS (NDA202811 SUPPL23)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202811\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=202811
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4bbd3f35d24ba5a03f5d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260520
DTEND;VALUE=DATE:20260521
SUMMARY:ABBV APPROVAL: VENCLEXTA
DESCRIPTION:Approved 2026-05-20: VENCLEXTA (NDA208573 SUPPL32)\nConfidence:
  confirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.f
 da.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208573
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4cae5fe722c4294b87db@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260422
DTEND;VALUE=DATE:20260423
SUMMARY:ABBV CRL: AGN-151586 for injection
DESCRIPTION:CRL 2026-04-22: AbbVie Inc. BLA 761459 (AGN-151586 for injectio
 n)\nConfidence: confirmed\nTicker ABBV (confidence 0.9)\nSource: https://d
 ownload.open.fda.gov/crl/CRL_BLA761459_20260422.pdf\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761459_20260422.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:43e4905bc0eb168afe9c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260306
DTEND;VALUE=DATE:20260307
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-03-06: SKYRIZI (BLA761105 SUPPL42)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9531bb224d3f70baa348@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260219
DTEND;VALUE=DATE:20260220
SUMMARY:ABBV APPROVAL: VENCLEXTA
DESCRIPTION:Approved 2026-02-19: VENCLEXTA (NDA208573 SUPPL31)\nConfidence:
  confirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.f
 da.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208573
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bb3a035d1ccd8c62c33b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251218
DTEND;VALUE=DATE:20251219
SUMMARY:ABBV APPROVAL: VRAYLAR
DESCRIPTION:Approved 2025-12-18: VRAYLAR (NDA204370 SUPPL17)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=204370
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0e738d99bfd31f28ac5e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251218
DTEND;VALUE=DATE:20251219
SUMMARY:ABBV APPROVAL: VRAYLAR
DESCRIPTION:Approved 2025-12-18: VRAYLAR (NDA204370 SUPPL15)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=204370
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:729e068fb378ac754c03@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251218
DTEND;VALUE=DATE:20251219
SUMMARY:ABBV APPROVAL: VRAYLAR
DESCRIPTION:Approved 2025-12-18: VRAYLAR (NDA204370 SUPPL16)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=204370
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:cddca98787a02c93c8f1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251218
DTEND;VALUE=DATE:20251219
SUMMARY:ABBV APPROVAL: VRAYLAR
DESCRIPTION:Approved 2025-12-18: VRAYLAR (NDA204370 SUPPL14)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=204370
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
